Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star

Shots:

• F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration
• Merck KGaA exercises its third option to develop an additional bispecific program under the ongoing collaboration with F-star
• Merck KGaA will be responsible for the development and commercialization of the preclinical program. In 2019, the companies collaborated with the first option to license while in July’2020, Merck KGaA brought the second program from the collaboration into its pipeline

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: PRNewswire